Ctemra (tocilizumab) - Risk Of Fatal Anaphylaxis - For Health Professionals

CTEMRA Recall Summary Tocilizumab (sold as CTEMRA) is being recalled in Canada because it carries a risk of fatal anaphylaxis, a severe allergic reaction. The recall affects all patients who use or may use this medication. Health professionals have been notified about this safety concern.

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2010-09-17

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/de953437-0750-4925-a432-93aac8d48544